[go: up one dir, main page]

MX2023014901A - Nanoparticulas que contienen acido nucleico. - Google Patents

Nanoparticulas que contienen acido nucleico.

Info

Publication number
MX2023014901A
MX2023014901A MX2023014901A MX2023014901A MX2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A MX 2023014901 A MX2023014901 A MX 2023014901A
Authority
MX
Mexico
Prior art keywords
nanoparticles
nucleic acid
acid containing
containing nanoparticles
cationic lipid
Prior art date
Application number
MX2023014901A
Other languages
English (en)
Inventor
Der Meel Roy Van
Willem J M Mulder
Ewelina Kluza
Stijn Hofstraat
Tom Anbergen
Robby Cornelis Zwolsman
Henricus Marie Janssen
Pieter Michele Fransen
Original Assignee
Bio Trip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Trip B V filed Critical Bio Trip B V
Publication of MX2023014901A publication Critical patent/MX2023014901A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen aquí nanopartículas que comprenden un fosfolípido, una apolipoproteína y/o mimético de apolipoproteína, esterol, lípido catiónico o lípido catiónico ionizable y un ácido nucleico; composiciones que comprenden estas nanopartículas; y un método de preparación de dichas nanopartículas; las nanopartículas se pueden usar como un medicamento, por ejemplo, para el tratamiento de una enfermedad estimulando o inhibiendo la respuesta inmunitaria innata.
MX2023014901A 2021-06-22 2022-06-22 Nanoparticulas que contienen acido nucleico. MX2023014901A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21180786 2021-06-22
PCT/EP2022/067073 WO2022268913A1 (en) 2021-06-22 2022-06-22 Nucleic acid containing nanoparticles

Publications (1)

Publication Number Publication Date
MX2023014901A true MX2023014901A (es) 2024-04-29

Family

ID=76553579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014901A MX2023014901A (es) 2021-06-22 2022-06-22 Nanoparticulas que contienen acido nucleico.

Country Status (10)

Country Link
US (1) US20240216291A1 (es)
EP (1) EP4358936A1 (es)
JP (1) JP2024526202A (es)
KR (1) KR20240025611A (es)
CN (1) CN117545467A (es)
AU (1) AU2022296780A1 (es)
CA (1) CA3222851A1 (es)
IL (1) IL309578A (es)
MX (1) MX2023014901A (es)
WO (1) WO2022268913A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023277740A1 (en) 2022-05-24 2024-11-07 Bio-Trip B.V. Modified apolipoproteins with a targeting body for lipid nanoparticles
EP4688163A1 (en) 2023-03-29 2026-02-11 Bio-TRIP B.V. Apolipoprotein lipid nanoparticle
WO2025190968A1 (en) 2024-03-11 2025-09-18 Bio-Trip B.V. Apolipoprotein lipid nanoparticle
CN120607455B (zh) * 2025-08-06 2025-10-21 中国科学院长春应用化学研究所 可电离脂质、其立体异构体或药学上可接受的盐、制备方法和应用
CN121059567A (zh) * 2025-11-07 2025-12-05 中国医学科学院输血研究所 一种脂质纳米颗粒及其应用、药物递送载体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302676A1 (en) * 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
KR101198354B1 (ko) * 2007-10-17 2013-03-14 주식회사 삼양바이오팜 핵산 전달용 저밀도 지단백질 유사(ＬＤＬ-ｌｉｋｅ) 양이온성 나노입자, 그의 제조방법 및 이를 이용한 핵산의 전달 방법
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
US8268796B2 (en) * 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
US20120101148A1 (en) * 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
WO2011044545A2 (en) * 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
EP3713548A4 (en) 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
GB201800370D0 (en) * 2018-01-10 2018-02-21 Ucl Business Plc Anionic nanocomplexes for nucleic acid delivery
WO2020206231A1 (en) * 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
CA3137565A1 (en) * 2019-04-26 2020-10-29 Northwestern University High density lipoprotein nanoparticles and rna templated lipoprotein particles for ocular therapy

Also Published As

Publication number Publication date
CA3222851A1 (en) 2022-12-29
EP4358936A1 (en) 2024-05-01
KR20240025611A (ko) 2024-02-27
JP2024526202A (ja) 2024-07-17
AU2022296780A9 (en) 2023-12-14
CN117545467A (zh) 2024-02-09
AU2022296780A1 (en) 2023-12-07
WO2022268913A1 (en) 2022-12-29
IL309578A (en) 2024-02-01
US20240216291A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
MX2023014901A (es) Nanoparticulas que contienen acido nucleico.
ZA202103233B (en) Lipid nanoparticle formulations
ZA202101465B (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
EP4635481A3 (en) Biodegradable lipids for the delivery of active agents
MX2022009018A (es) Nanoparticulas lipidas.
ZA202300131B (en) Lipid nanoparticles
MX2022007680A (es) Nanoparticulas lipidicas para administracion de acidos nucleicos.
WO2020051220A8 (en) Compositions and methods for organ specific delivery of nucleic acids
EP3964200A1 (en) Compositions and methods for delivery of therapeutic agents
JOP20200050A1 (ar) عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام
EP4632075A3 (en) Method for reducing immunogenicity of rna
BR112018006489A2 (pt) composições e métodos para inibir a expressão gênica de lpa
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
MX2012014079A (es) Lipidos biodegradables para la administracion de agentes activos.
HK1250009A1 (zh) 用於将rna和水溶性治疗有效化合物递送到靶细胞的脂质颗粒制剂
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2017015037A (es) Composiciones nutritivas que contienen un nivel elevado de inositol y usos de las mismas.
IN2015DN03219A (es)
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
BRPI0417932A (pt) lipólise medicamentosa de acúmulo de gordura
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
ZA202403337B (en) Lipid nanoparticles for oligonucleotide delivery
MX341918B (es) Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.